<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-GB">
	<id>https://stockhub.co/index.php?action=history&amp;feed=atom&amp;title=Saniona_AB</id>
	<title>Saniona AB - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://stockhub.co/index.php?action=history&amp;feed=atom&amp;title=Saniona_AB"/>
	<link rel="alternate" type="text/html" href="https://stockhub.co/index.php?title=Saniona_AB&amp;action=history"/>
	<updated>2026-05-24T23:45:50Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.5</generator>
	<entry>
		<id>https://stockhub.co/index.php?title=Saniona_AB&amp;diff=52288&amp;oldid=prev</id>
		<title>&gt;Paris: Created page with &quot;== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; ==  Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company&#039;s products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalami...&quot;</title>
		<link rel="alternate" type="text/html" href="https://stockhub.co/index.php?title=Saniona_AB&amp;diff=52288&amp;oldid=prev"/>
		<updated>2022-08-16T04:41:04Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;== Summary&amp;lt;ref&amp;gt;Source: Yahoo Finance.&amp;lt;/ref&amp;gt; ==  Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company&amp;#039;s products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalami...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;== Summary&amp;lt;ref&amp;gt;Source: Yahoo Finance.&amp;lt;/ref&amp;gt; ==&lt;br /&gt;
&lt;br /&gt;
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company&amp;#039;s products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.&lt;br /&gt;
&lt;br /&gt;
== References and notes == &lt;br /&gt;
[[Category:Thesis]]&lt;br /&gt;
__INDEX__&lt;/div&gt;</summary>
		<author><name>&gt;Paris</name></author>
	</entry>
</feed>